Sodium adenosine triphosphate (Adenosintriphosphate sodium)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceTrifosadeninTrifosadenin
Dosage form: & nbspsolution for intravenous administration
Composition:

1 ml of the solution contains active substance adenosine triphosphate of disodium salt (trifosadenin) - 0.01 g.

Excipients: sodium hydroxide 2 M solution (up to pH 7.0-7.3), water for injection.

Description:

Colorless or slightly yellowish transparent liquid.

Pharmacotherapeutic group:Metabolic means
ATX: & nbsp

C.01.E.B   Other drugs for the treatment of heart disease

Pharmacodynamics:Sodium adenosine triphosphate (ATP) is a metabolic drug, has antiarrhythmic effect, also has antihypertensive effect, expands coronary and cerebral arteries. Is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic digestion of carbohydrates.Contained in many organs and tissues, but most of all - in skeletal muscles. Improves metabolism and energy supply of tissues. Due to its cleavage into adenosine diphosphoric acid and inorganic phosphate, ATP releases a large amount of energy used for muscle contraction, protein synthesis, urea, intermediate products of metabolism, etc. Under the influence of ATP, blood pressure decreases and smooth muscle relaxes, nerve impulses in autonomic ganglia and transmission of excitation from the vagus nerve to the heart, increased myocardial contractility. After parenteralof the introduction penetrates into the cells of the organs, where it is split into adenosine and inorganic phosphate with energy release. Subsequently, cleavage products are included in the resynthesis of ATP.
Pharmacokinetics:
Indications:Suppression of paroxysms of supraventricular tachycardia (excluding fibrillation and / or atrial flutter).
Contraindications:

Hypersensitivity, acute myocardial infarction, arterial hypotension, infectious and inflammatory lung diseases.

Dosing and Administration:

The drug is injected intravenously rapidly into the central or large peripheral vein 3 mg for 2 seconds under the control of the electrocardiogram and blood pressure; if necessary, after 1-2 minutes re-injected 6 mg of the drug, after 1-2 minutes - 12 mg; administration is discontinued with the development of atrioventricular blockade at any of the stages of drug administration.

Side effects:

Possible allergic reactions (itching, flushing of the skin), nausea, hyperemia of the skin of the face, headache, weakness; after arresting the paroxysm of tachycardia, there may be short-term episodes of sinus bradycardia and / or atrioventricular blockade I-III degree (ECG control).

Overdose:

There was no evidence of an overdose.

Interaction:

Cardiac glycosides increase the risk of side effects (including arrhythmogenic effects). Dipyridamole strengthens the effect; theophylline, caffeine and other methyl xanthines - weaken.

Special instructions:

Do not administer in large doses simultaneously with cardiac glycosides.

Form release / dosage:Solution for intravenous administration 10 mg / ml.
Packaging:

Into ampoules of 1 ml. 10 ampoules are placed in a pack (box) of cardboard along with the instructions for use, a ampoule or ampoule knife with a knife.If you use ampoules that have a break ring or an opening point, the ampoule knife (scarifier) ​​is not inserted.

Storage conditions:

In a dry, dark place at a temperature of 2 to 10 ° C.

Keep out of the reach of children.

Shelf life:1 year. Do not use after the expiration date printed on the package.
Terms of leave from pharmacies:On prescription
Registration number:LSR-002745/10
Date of registration:01.04.2010 / 17.07.2013
Expiration Date:Unlimited
The owner of the registration certificate:MICROGEN FGUP Scientific and Production Association MICROGEN FGUP Scientific and Production Association Russia
Manufacturer: & nbsp
Information update date: & nbsp23.05.2018
Illustrated instructions
    Instructions
    Up